A detailed history of Banque Pictet & Cie Sa transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Banque Pictet & Cie Sa holds 73,883 shares of APLS stock, worth $2.03 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
73,883
Holding current value
$2.03 Million
% of portfolio
0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$28.84 - $41.15 $2.13 Million - $3.04 Million
73,883 New
73,883 $2.13 Million
Q3 2023

Nov 02, 2023

SELL
$23.65 - $89.22 $115,719 - $436,553
-4,893 Reduced 4.57%
102,242 $3.89 Million
Q2 2023

Aug 04, 2023

SELL
$76.68 - $93.31 $2.41 Million - $2.94 Million
-31,467 Reduced 22.7%
107,135 $9.76 Million
Q1 2023

May 01, 2023

SELL
$46.59 - $66.96 $946,848 - $1.36 Million
-20,323 Reduced 12.79%
138,602 $9.14 Million
Q4 2022

Feb 06, 2023

SELL
$43.24 - $61.04 $434,389 - $613,207
-10,046 Reduced 5.95%
158,925 $0
Q3 2022

Nov 10, 2022

SELL
$44.76 - $69.66 $473,516 - $736,933
-10,579 Reduced 5.89%
168,971 $11.5 Billion
Q2 2022

Aug 08, 2022

SELL
$35.07 - $59.21 $339,232 - $572,738
-9,673 Reduced 5.11%
179,550 $8.12 Million
Q1 2022

May 04, 2022

BUY
$35.46 - $54.12 $735,227 - $1.12 Million
20,734 Added 12.31%
189,223 $9.61 Million
Q4 2021

Feb 02, 2022

BUY
$30.74 - $49.16 $4.66 Million - $7.45 Million
151,606 Added 897.98%
168,489 $7.97 Million
Q3 2021

Nov 10, 2021

SELL
$31.4 - $69.84 $180,298 - $401,021
-5,742 Reduced 25.38%
16,883 $556,000
Q2 2021

Aug 12, 2021

BUY
$40.9 - $64.9 $42,822 - $67,950
1,047 Added 4.85%
22,625 $1.43 Million
Q1 2021

May 11, 2021

BUY
$40.8 - $57.39 $880,382 - $1.24 Million
21,578 New
21,578 $926,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.01B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Banque Pictet & Cie Sa Portfolio

Follow Banque Pictet & Cie Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

News

Stay updated on Banque Pictet & Cie Sa with notifications on news.